CIDER Biotech Pty Ltd

Cider Biotech has developed a unique bio-engineering platform focused on enzyme-based protein switch engineering for diagnostic and therapeutic applications. The company’s core technology, known as the FleX Switch, utilizes a modular architecture designed to convert various sensing inputs—such as ions, small molecules, lipids, peptides, proteins, DNA, and RNA—into specific reporting outputs like fluorescence, luminescence, or electric current. By moving away from traditional models that build hardware around natural proteins, Cider Biotech creates bespoke biosensors tailored to specific ligands, offering greater versatility and manufacturing efficiency compared to conventional methods.

This technology provides assay developers with tools to design innovative diagnostic products suitable for environments ranging from high-volume central laboratories to point-of-care and wearable devices. Founded in 2024 by Professor Kirill Alexandrov and entrepreneur Matt Cooper, the company aims to reduce reagent development time and lower manufacturing costs. Their solutions are intended to empower the medical and industrial sectors by enabling the creation of simple, homogeneous assays that rely on minimal components to achieve highly sensitive detection.